Overview

Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer. The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients. This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.

Full Product Details

Author:   Frank E Johnson ,  Yoshihiko Maehara ,  George P Browman ,  Julie A. Margenthaler
Publisher:   Humana Press Inc.
Imprint:   Humana Press Inc.
Edition:   2013 ed.
Dimensions:   Width: 21.00cm , Height: 2.90cm , Length: 27.90cm
Weight:   1.935kg
ISBN:  

9781627039659

ISBN 10:   1627039651
Pages:   538
Publication Date:   02 April 2015
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

1. Overview David Y. Johnson and Frank E. Johnson   2. Introduction to Cancer Surveillance Strategies Brooke Crawford and David D. Greenberg   3. Using Decision Analysis to Model Cancer Surveillance Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg   4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment Craig C. Earle and Jennifer Deevy   5. Upper Aerodigestive Tract Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe Béatrix Barry and Dominique De Raucourt   7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune   8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada Richard W. Nason and James B. Butler   9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia Leigh Delbridge   11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune   12. Lung Carcinoma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   13. Lung Carcinoma Surveillance Counterpoint: Australia Michael Boyer and Kate Mahon   14. Lung Carcinoma Surveillance Counterpoint: Japan Tokujiro Yano and Yoshihiko Maehara   15. Lung Carcinoma Surveillance Counterpoint: Canada Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans   16. Esophagus Carcinoma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   17. Esophagus Carcinoma Surveillance Counterpoint: Australia Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister   18. Esophagus Carcinoma Surveillance Counterpoint: Japan Masaru Morita and Yoshihiko Maehara   19. Stomach Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   20. Stomach Carcinoma Surveillance Counterpoint: USA Andrew Coleman and Douglas Tyler   21. Stomach Carcinoma Surveillance Counterpoint: Japan Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara   22. Pancreatic Adenocarcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA Tanios S. Bekaii-Saab   24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe Richard A. Smith, Jane V. Butler, and John P. Neoptolemos   25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan Ken Shirabe and Yoshihiko Maehara   26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada Malcolm J. Moore and Anastasios Stathis   27. Liver and Biliary Tract Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe Michele Colledan   29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia Michael D. Crawford   30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan Akinobu Taketomi and Yoshihiko Maehara   31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada Oliver F. Bathe and Kelly Warren Burak   32. Colon and Rectum Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA Mohamedtaki A. Tejani and Steven J. Cohen   34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia Toufic El-Khoury, Michael Solomon, and Jane Young   35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan Yasushi Toh and Yoshihisa Sakaguchi   36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada Marko Simunovic   37. Anal Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   38. Anal Carcinoma Surveillance Counterpoint: USA Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata   39. Anal Carcinoma Surveillance Counterpoint: Australia Toufic El-Khoury, Michael Solomon, and Jane Young   40. Anal Carcinoma Surveillance Counterpoint: Japan Yoshihisa Sakaguchi and Yasushi Toh   41. Anal Carcinoma Surveillance Counterpoint: Canada Natasha Press and John Hay   42. Soft Tissue Sarcoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   43. Soft Tissue Sarcoma Surveillance Counterpoint: USA Valeriy Sedov and Janice M. Mehnert   44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan Shuichi Matsuda and Yukihide Iwamoto   45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada Lloyd A. Mack and Vivien H.C. Bramwell   46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan Shuichi Matsuda and Yukihide Iwamoto   48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada Timothy R. Asmis, Joel Werier, and Shailendra Verma   49. Cutaneous Melanoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   50. Cutaneous Melanoma Surveillance Counterpoint: USA Gerald Linette and Lynn A. Cornelius   51. Cutaneous Melanoma Surveillance Counterpoint: Australia Michael A. Henderson   52. Cutaneous Melanoma Surveillance Counterpoint: Japan Yoichi Moroi   53. Breast Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   54. Breast Carcinoma Surveillance Counterpoint: USA Kelli Pettit and Julie A. Margenthaler   55. Breast Carcinoma Surveillance Counterpoint: Europe Stefano Ciatto   56. Breast Carcinoma Surveillance Counterpoint: Australia Andrew J. Spillane and Meagan E. Brennan   57. Breast Carcinoma Surveillance Counterpoint: Japan Eriko Tokunaga and Yoshihiko Maehara   58. Endometrial Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   59. Endometrial Cancer Surveillance Counterpoint: USA Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.   60. Endometrial Cancer Surveillance Counterpoint: USA Summer B. Dewdney and Premal H. Thaker   61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake   62. Endometrial Carcinoma Surveillance Counterpoint: Canada Michael Fung-Kee-Fung and Thomas K. Oliver   63. Cervical Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   64. Cervical Carcinoma Surveillance Counterpoint: USA Joshua P. Kesterson and Shashikant Lele   65. Cervical Carcinoma Surveillance Counterpoint: Japan Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake   66. Cervical Carcinoma Surveillance Counterpoint: Canada Michael Fung-Kee-Fung and Thomas K. Oliver   67. Vaginal and Vulvar Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake   69. Ovarian Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   70. Ovarian Carcinoma Surveillance Counterpoint: USA Maurie Markman   71. Ovarian Cancer Surveillance Counterpoint: Europe Andy Nordin   72. Ovarian Cancer Surveillance Counterpoint: Japan Hiroaki Kobayashi and Norio Wake   73. Renal Carcinoma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   74. Renal Carcinoma Surveillance Counterpoint: Europe Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico   75. Renal Carcinoma Surveillance Counterpoint: Japan Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada   76. Renal Carcinoma Surveillance Counterpoint: Canada Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett   77. Urinary Bladder Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan Kentaro Kuroiwa   79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada Faysal A. Yafi and Wassim Kassouf   80. Prostate Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   81. Prostate Carcinoma Surveillance Counterpoint: USA Angela Smith and Raj Pruthi   82. Prostate Carcinoma Surveillance Counterpoint: USA  Erik T. Goluboff and Matthew Wosnitzer   83. Prostate Carcinoma Surveillance Counterpoint: Europe Stefano Ciatto   84. Prostate Carcinoma Surveillance Counterpoint: Japan Akira Yokomizo   85. Prostate Carcinoma Surveillance Counterpoint: Canada Andrew Loblaw and Colin Tang   86. Testicle Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   87. Testicle Carcinoma Surveillance Counterpoint: USA Ian M. Thompson III and Sam S. Chang   88. Testicle Carcinoma Surveillance Counterpoint: Australia Michael Boyer and Kate Mahon   89. Testicle Carcinoma Surveillance Counterpoint: Japan Narihito Seki   90. Lymphoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   91. Lymphoma Surveillance Counterpoint: USA Kenneth R. Carson and Nancy L. Bartlett   92. Lymphoma Surveillance Counterpoint: Japan Kenjiro Kamezaki   93. Lymphoma (Following Autologous Stem Cell Transplant) Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan Toshihiro Miyamoto   95. Leukemia David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   96. Leukemia Surveillance Counterpoint: USA Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy   97. Leukemia Surveillance Counterpoint: Japan Koji Nagafuji   98. Multiple Myeloma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson   99. Multiple Myeloma Surveillance Counterpoint: USA Niyati Modi, G. David Roodman, and Suzanne Lentzsch   100. Multiple Myeloma Surveillance Counterpoint: Australia Liane Khoo and Douglas Joshua   101. Multiple Myeloma Surveillance Counterpoint: Japan Katsuto Takenaka   102. Multiple Myeloma Surveillance Counterpoint: Canada Matthew C. Cheung and Kevin R. Imrie   103. Glioma of the Central Nervous System David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson   104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo   105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia Margot Lehman and Michael Barton   106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki

Reviews

From the reviews: This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. ... Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. ... This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent. (Judith G. Abramson, Doody's Book Reviews, September, 2013) Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. ... This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library. (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)

From the reviews: This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent. (Judith G. Abramson, Doody s Book Reviews, September, 2013) Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library. (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)

Author Information

Dr. Frank E. Johnson, MD

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions